Zentalis Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Insider Trading Arrangements and Policies.
On June 18, 2025, Vincent Vultaggio, the Company’s Senior Vice President, Finance and Principal Accounting Officer and interim principal financial officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of a to-be-determined number of shares of the Company’s common stock until February 26, 2027. The actual number of shares to be sold under the Rule 10b5-1 trading arrangement will equal 15% of shares received upon the occurrence of future restricted stock unit vesting events, net of any shares sold to cover tax obligations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.